Strategic and visionary leader with extensive experience in biopharmaceutical corporate affairs, communications, and investor relations. Currently serving as Vice President, Corporate Affairs at Bristol Myers Squibb, leading government affairs, advocacy and communications efforts related to the Company’s psychiatry portfolio, including Cobenfy (xanomeline-trospium). Prior to joining Bristol Myers Squibb, served as Vice President, Corporate Affairs & Investor Relations and member of the Executive Leadership team at Karuna Therapeutics until its acquisition by Bristol Myers Squibb in March 2024.
Listed skills include Leadership, Product Marketing, Powerpoint, Social Media, and 19 others.